WB, IP, FC-FP
H
Endogenous
40-50
Rabbit IgG
#P55899
2217
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
| Flow Cytometry (Fixed/Permeabilized) | 1:50 - 1:200 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human FcRn protein.
Background
The neonatal Fc receptor, FcRn, is an atypical Fc gamma receptor that bears homology to class I MHC (major histocompatibility complex) and associates with β2-microglobulin (1). FcRn is expressed by the vascular endothelium, several epithelial cell types, and hematopoietic cells including several innate immune cell types and B cells (2). FcRn mediates recycling and transcytosis of IgG, resulting in protection of IgG from catabolism and an extended serum half-life of IgG relative to other antibody isotypes (3). In addition, FcRn transports IgG across the placenta and also mediates uptake of maternal IgG from milk, resulting in enhanced humoral immunity in the fetus and neonates (1,4,5). FcRn also plays an important role in initiation of adaptive immunity by transporting immune complexes to intracellular dendritic cell compartments for antigen processing and presentation to T cells (6-8). In addition to IgG, FcRn also binds albumin and similarly protects it from catabolism, leading to extended half-life and high plasma concentrations (9).
- Simister, N.E. and Mostov, K.E. (1989) Nature 337, 184-7.
- Pyzik, M. et al. (2015) J Immunol 194, 4595-603.
- Roopenian, D.C. et al. (2003) J Immunol 170, 3528-33.
- Story, C.M. et al. (1994) J Exp Med 180, 2377-81.
- Raghavan, M. et al. (1994) Immunity 1, 303-15.
- Yoshida, M. et al. (2006) Springer Semin Immunopathol 28, 397-403.
- Qiao, S.W. et al. (2008) Proc Natl Acad Sci U S A 105, 9337-42.
- Baker, K. et al. (2011) Proc Natl Acad Sci U S A 108, 9927-32.
- Chaudhury, C. et al. (2003) J Exp Med 197, 315-22.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation FC-FP: Flow Cytometry (Fixed/Permeabilized)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
